{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:07:42Z","timestamp":1790834862045,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"DOI":"10.7759\/cureus.91652","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:11:57Z","timestamp":1757070717000},"source":"Crossref","is-referenced-by-count":3,"title":["Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Arwa","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alasmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Aletani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Ezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sereen","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki F","family":"Alasmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husain","family":"Alalgum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhannad","family":"Bin Sawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong Q","year":"2021","unstructured":"Kong Q, Ming WK, Mi XS. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. BMJ Open. 2021, 11:e042384. 10.1136\/bmjopen-2020-042384","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen J","year":"2007","unstructured":"Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007, 10:133-40. 10.1007\/s10456-007-9066-0","journal-title":"Angiogenesis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009734.pub3","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar MJ","year":"2018","unstructured":"Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018, 1:CD009734. 10.1002\/14651858.CD009734.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis","volume":"13","author":"Wang SD","year":"2020","unstructured":"Wang SD, Zhang GM. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int J Ophthalmol. 2020, 13:806-15. 10.18240\/ijo.2020.05.17","journal-title":"Int J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04946-8","article-title":"Does the number of laser applications for ROP treatment influence the degree of myopia?","volume":"259","author":"Inoue T","year":"2021","unstructured":"Inoue T, Asaoka R, Hashimoto Y, et al.. Does the number of laser applications for ROP treatment influence the degree of myopia?. Graefes Arch Clin Exp Ophthalmol. 2021, 259:317-22. 10.1007\/s00417-020-04946-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2022.22308","article-title":"Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration","volume":"10","author":"Sahin O","year":"2023","unstructured":"Sahin O, Boga A, Hacioglu GK, et al.. Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration. North Clin Istanb. 2023, 10:470-6. 10.14744\/nci.2022.22308","journal-title":"North Clin Istanb"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay M","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017, 42:462-9. 10.1080\/02713683.2016.1196709","journal-title":"Curr Eye Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry GP","year":"2021","unstructured":"Barry GP, Yu Y, Ying GS, et al.. Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2021, 128:1188-96. 10.1016\/j.ophtha.2020.12.028","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling KP","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, et al.. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina. 2020, 40:1793-803. 10.1097\/IAE.0000000000002663","journal-title":"Retina"},{"key":"ref10","unstructured":"CASP. CASP checklists. (2018). Accessed: September 5, 2025: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl A","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al.. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019, 394:1551-9. 10.1016\/s0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh R","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al.. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016, 94:e417-20. 10.1111\/aos.13008","journal-title":"Acta Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang G","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, et al.. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017, 37:710-7. 10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner HA","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011, 364:603-15. 10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl A","year":"2022","unstructured":"Stahl A, Sukgen EA, Wu WC, et al.. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial. JAMA. 2022, 328:348-59. 10.1001\/jama.2022.10564","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang E","year":"2022","unstructured":"Chang E, Josan AS, Purohit R, et al.. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology. 2022, 129:1389-401. 10.1016\/j.ophtha.2022.06.042","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen J","year":"2023","unstructured":"Chen J, Hao Q, Zhang J, et al.. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis. Ital J Pediatr. 2023, 49:136. 10.1186\/s13052-023-01543-3","journal-title":"Ital J Pediatr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406102-retreatment-and-reactivation-rates-following-bevacizumab-ranibizumab-aflibercept-and-laser-for-retinopathy-of-prematurity-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:12:00Z","timestamp":1757070720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406102-retreatment-and-reactivation-rates-following-bevacizumab-ranibizumab-aflibercept-and-laser-for-retinopathy-of-prematurity-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.91652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}